Table 3 Antimicrobial resistance rates of clinical isolates of community-acquired (CA), healthcare-associated (HCA), and nosocomial K. pneumoniae bacteremia
Variable | CA (n = 70) | HCA (n = 102) | Nosocomial (n = 165) | p value | ||
|---|---|---|---|---|---|---|
CA vs. HCA | HCA vs. Nosocomial | CA vs. Nosocomial | ||||
Amikacin | 0 (0.0) | 1 (1.0) | 7 (4.2) | 1.000 | 0.160 | 0.107 |
Gentamicin | 1 (1.4) | 15 (14.7) | 35 (21.2) | 0.003 | 0.185 | < 0.001 |
Cefuroxime | 2 (2.9) | 23 (22.5) | 67 (40.6) | < 0.001 | 0.002 | < 0.001 |
Ceftriaxone | 1 (1.4) | 12 (11.8) | 52 (31.5) | 0.016 | < 0.001 | < 0.001 |
Cefepime | 0 (0.0) | 6 (5.9) | 24 (14.5) | 0.082 | 0.029 | < 0.001 |
Ciprofloxacin | 1 (1.4) | 11 (10.8) | 49 (29.7) | 0.029 | < 0.001 | < 0.001 |
Levofloxacin | 1 (1.4) | 11 (10.8) | 48 (29.1) | 0.029 | < 0.001 | < 0.001 |
Ertapenem | 0 (0.0) | 7 (6.9) | 27 (16.4) | 0.042 | 0.024 | < 0.001 |
Imipenem | 0 (0.0) | 1 (1.0) | 14 (8.5) | 1.000 | 0.011 | 0.012 |
Tigecycline | 2 (2.9) | 3 (2.9) | 5 (3.0) | 1.000 | 1.000 | 1.000 |
Trimethoprim-sulfamethoxazole | 5 (7.1) | 25 (24.5) | 61 (37.0) | 0.003 | 0.034 | < 0.001 |
Wild-type antibiotic susceptibilitya | 60 (85.7) | 67 (65.7) | 78 (47.3) | 0.003 | 0.003 | < 0.001 |
Multidrug resistanceb | 4 (5.7) | 24 (23.5) | 69 (41.8) | 0.002 | 0.002 | < 0.001 |